Core Insights - Sidra Medicine has been awarded a $100,000 G-Rex® Grant to develop a CAR-T cell production platform focused on pediatric oncology [1][2] - The grant will facilitate the preclinical development of a CD19 CAR-T cell therapy product and support the implementation of a fully closed system, semi-automated G-Rex production compliant with current Good Manufacturing Practices (cGMPs) [2][3] - ScaleReady's G-Rex Grant Program has committed over $40 million to advance cell and gene-modified cell therapy (CGT) development and manufacturing [5] Company Developments - Sidra Medicine aims to enhance treatment protocols for pediatric diseases, leveraging the G-Rex® method for efficient T cell manufacturing [3][4] - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials [8] - ScaleReady has introduced a new program, LEAN Cell & Gene™, to help CGT entities improve operational efficiency and product quality [6] Industry Context - The G-Rex centric manufacturing process offers significant technical and economic advantages for CAR-T manufacturing in Qatar and the Middle East [4] - The G-Rex Grant recipients gain access to exclusive support from ScaleReady's consortium, enhancing their capabilities in cGMP manufacturing and regulatory affairs [5][9] - Bio-Techne Corporation collaborates with Wilson Wolf to provide tailored products for G-Rex® Bioreactors, supporting high throughput closed-system manufacturing [11]